Skip to main content

Advertisement

SpringerLink
Log in

Current Management of Peritoneal Carcinomatosis From Colorectal Cancer: the Role of Cytoreductive Surgery and Hyperthermic Peritoneal Chemoperfusion

  • Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is a disease with a poor prognosis, often thought to be a terminal illness with no hope except for palliative treatment. New therapeutic modalities combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown favorable outcomes and may provide a significant survival benefit in a selected group of patients. The main rational for CRS is to remove all visible tumor burden to allow for the chemotherapeutic agent (HIPEC) to eradicate any microscopic residual disease. The Amsterdam statement formulated at the 9th International Congress on Peritoneal Surface Malignancies supports the use of CRS with HIPEC as a standard of care for selected patients with small-to-moderate volume PC from CRC. Selecting appropriate patients who would benefit from CRS/HIPEC is paramount to derive the maximum oncological outcomes while minimizing the risks of postoperative complications and mortality. In this paper, we will review the role for CRS/HIPEC in the management of PC from CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–23.

    Article  PubMed  Google Scholar 

  2. Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol. 1983;22:95–9. Wiley Subscription Services, Inc., A Wiley Company.

    Article  CAS  PubMed  Google Scholar 

  3. Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364–7. Wiley Subscription Services, Inc., A Wiley Company.

    Article  CAS  PubMed  Google Scholar 

  4. Knorr C, Reingruber B, Meyer T, Hohenberger W, Stremmel C. Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities. Int J Colorectal Dis. 2004;19:181–7. Springer-Verlag.

    Article  CAS  PubMed  Google Scholar 

  5. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92. American Society of Clinical Oncology.

    Article  CAS  PubMed  Google Scholar 

  6. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, De Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717–25. Wiley Subscription Services, Inc., A Wiley Company.

    Article  CAS  PubMed  Google Scholar 

  7. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705. John Wiley & Sons, Ltd.

    Article  CAS  PubMed  Google Scholar 

  8. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.

    Article  CAS  PubMed  Google Scholar 

  9. Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19:4052–8. Springer-Verlag.

    Article  CAS  PubMed  Google Scholar 

  10. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42. American Society of Clinical Oncology.

    Article  PubMed  Google Scholar 

  11. Alexander HR, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779–86.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–6. Springer-Verlag.

    Article  PubMed  Google Scholar 

  13. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol. 2005;12:765–77. Springer-Verlag.

    Article  PubMed  Google Scholar 

  14. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009.

  15. Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 2009;21:665–74.

    Article  CAS  PubMed  Google Scholar 

  16. Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, Müller R, Wagner E, et al. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Ther. 2014;13:926–37. American Association for Cancer Research.

    Article  CAS  PubMed  Google Scholar 

  17. de Cuba EMV, Kwakman R, Van Egmond M, Bosch LJW, Bonjer HJ, Meijer GA, et al. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer. Virchows Arch. 2012;461:231–43. Springer-Verlag.

    Article  PubMed  Google Scholar 

  18. Sommariva A, Rossi CR. Peritoneal carcinomatosis from colorectal Cancer. Treatment of peritoneal surface malignancies. Springer, Milan; 2015. p. 271–94.

  19. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Peritoneal carcinomatosis: principles of management. Boston: Springer US; 1996. p. 79–100.

    Google Scholar 

  20. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70:163–9.

    CAS  PubMed  Google Scholar 

  21. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307–17.

    CAS  PubMed  Google Scholar 

  22. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep. 1976;60:1749–60.

    CAS  PubMed  Google Scholar 

  23. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39:3861–5. American Association for Cancer Research.

    CAS  PubMed  Google Scholar 

  24. Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol. 1985;248:F413–24. American Physiological Society.

    CAS  PubMed  Google Scholar 

  25. Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T. Pharmacokinetic characteristics of 5‐fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46:685–9. Blackwell Publishing Ltd.

    Article  CAS  PubMed  Google Scholar 

  26. Israel VK, Jiang C, Muggia FM, Tulpule A, Jeffers S, Leichman L, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol. 1995;37:32–8. Springer-Verlag.

    Article  CAS  PubMed  Google Scholar 

  27. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72. Oxford University Press.

    Article  CAS  PubMed  Google Scholar 

  28. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 1980;40:1165–8. American Association for Cancer Research.

    CAS  PubMed  Google Scholar 

  29. El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6:117–27. Elsevier.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Dig Surg. 2001;18:260–73. Karger Publishers.

    Article  CAS  PubMed  Google Scholar 

  31. Runowicz CD, Dottino PR, Shafir MK, Mark MA, Cohen CJ. Catheter complications associated with intraperitoneal chemotherapy. Gynecol Oncol. 1986;24:41–50. Academic Press.

    Article  CAS  PubMed  Google Scholar 

  32. Sugarbaker PH. Peritonectomy procedures. Peritoneal Carcinomatosis. 2007.

  33. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43:S15–25. Springer-Verlag.

    Article  PubMed  Google Scholar 

  34. 5th International workshop on peritoneal surface malignancy [Internet]. [cited 2016 Nov 27]. p. 1–3. Available from: http://www.peritonealworkshop2006.com/voting_5.php

  35. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992;52:487–90.

    CAS  PubMed  Google Scholar 

  36. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48:7022–32. American Association for Cancer Research.

    CAS  PubMed  Google Scholar 

  37. Bao P, Bartlett D. Surgical techniques in visceral resection and peritonectomy procedures. Cancer J. 2009;15:204–11.

    Article  PubMed  Google Scholar 

  38. Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98:247–52. Wiley Subscription Services, Inc., A Wiley Company.

    Article  PubMed  Google Scholar 

  39. •• Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2013;21:1501–5. Springer US. This paper presents the guidelines for the treatment of peritoneal carcinomatosis from colorectal studies in the US.

  40. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs. 1990;1:5–13.

    Article  CAS  PubMed  Google Scholar 

  41. de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Advances in peritoneal surface oncology. Berlin: Springer Berlin Heidelberg; 2007. p. 53–73.

    Google Scholar 

  42. Verwaal VJ. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.

    Article  PubMed  Google Scholar 

  43. Clinical Trials register - PRODIGE 7 [Internet]. [cited 2017 Jan 25]. p. 1–3. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=PRODIGE+7.

  44. Nassour I, Polanco PM. Minimally invasive liver surgery for hepatic colorectal metastases. Curr Colorectal Cancer Rep. 2016;1–10. Springer US.

  45. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.

    Article  PubMed  Google Scholar 

  46. • Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American College of Surgeons national surgical quality improvement program. JAMA Surg. 2014;149:170–5. American Medical Association. This paper presents the morbidity and mortality rates following HIPEC in a national cohort of patients.

  47. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.

    Article  PubMed  Google Scholar 

  48. Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9. Springer-Verlag.

    Article  CAS  PubMed  Google Scholar 

  49. Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53. Wiley Subscription Services, Inc., A Wiley Company.

    Article  PubMed  Google Scholar 

  50. Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2008;15:754–63.

    Article  PubMed  Google Scholar 

  51. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–6.

    Article  CAS  PubMed  Google Scholar 

  52. Reuter NP, MacGregor JM, Woodall CE, Sticca RP, William C, Helm MB, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg. 2008;196:909–14.

    Article  PubMed  Google Scholar 

  53. • Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol. 2014;22:1673–9. Springer US. This paper defines the learning curve for CRS/HIPEC and the impact on perioperative and oncologic outcomes.

  54. Smeenk RM, Verwaal VJ, Zoetmulder FAN. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408–14. John Wiley & Sons, Ltd.

    Article  CAS  PubMed  Google Scholar 

  55. Kusamura S, Baratti D, Virzì S, Bonomi S, Iusco DR, Grassi A, et al. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol. 2013;107:312–9. Wiley Subscription Services, Inc., A Wiley Company.

    Article  PubMed  Google Scholar 

  56. Jayne DG, Fook S, Loi C, Seow CF. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50. Blackwell Science Ltd.

    Article  CAS  PubMed  Google Scholar 

  57. Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2016. American Society of Clinical Oncology.

  59. Colon cancer NCCN evidence blocks [Internet]. 2nd ed. [cited 2016 Nov 27]. p. 1–163. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf.

  60. Li Y, Yu Y, Liu Y. Report on the 9th International Congress on Peritoneal Surface Malignancies. Cancer Biol Med. 2014;11:281–4.

    PubMed  PubMed Central  Google Scholar 

  61. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14:128–33. Springer-Verlag.

    Article  CAS  PubMed  Google Scholar 

  62. Elias D, Gilly F, Boutitie F, Quenet F, Bereder J-M, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8. American Society of Clinical Oncology.

    Article  PubMed  Google Scholar 

  63. Weber T, Roitman M, Link KH. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. CLCC. 2012;11:167–76. Elsevier.

    Google Scholar 

  64. Elias D, Raynard B, Farkhondeh F, Goéré D, Rouquie D, Ciuchendea R, et al. Peritoneal carcinomatosis of colorectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol. 2006;30:1200–4.

    Article  CAS  PubMed  Google Scholar 

  65. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe J-M, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009. American Society of Clinical Oncology.

  66. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62. Wiley Subscription Services, Inc., A Wiley Company.

    Article  PubMed  Google Scholar 

  67. Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18:1560–7. Springer-Verlag.

  68. •• Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32. Springer-Verlag. This is the only randomized trial comparing CRS/HIPEC versus chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

  69. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33. American Medical Association.

    Article  CAS  PubMed  Google Scholar 

  70. Satoh Y, Ichikawa T, Motosugi U, Kimura K, Sou H, Sano K, et al. Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT. Am J Roentgenol. 2011;196:447–53.

    Article  Google Scholar 

  71. Low RN, Barone RM, Lee MJ. Surveillance MR imaging is superior to serum tumor markers for detecting early tumor recurrence in patients with appendiceal cancer treated with surgical cytoreduction and HIPEC. Ann Surg Oncol. 2013;20:1074–81.

    Article  PubMed  Google Scholar 

  72. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Peritoneal carcinomatosis: principles of management. Boston: Springer US; 1996. p. 359–74.

    Book  Google Scholar 

  73. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–46. John Wiley & Sons, Ltd.

    Article  CAS  PubMed  Google Scholar 

  74. Swellengrebel HAM, Zoetmulder FAN, Smeenk RM, Antonini N, Verwaal VJ. Quantitative intra-operative assessment of peritoneal carcinomatosis—a comparison of three prognostic tools. Eur J Surg Oncol (EJSO). 2009;35:1078–84.

    Article  CAS  Google Scholar 

  75. Kwakman R, Schrama AM, van Olmen JP, Otten RH, de Lange-de Klerk ES, de Cuba EM, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263:1102–11.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dave Primm for his help in editing this manuscript.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8548, USA

    Ibrahim Nassour & Patricio M. Polanco

  2. Department of Veterans Affairs, VA North Texas Health Care System, Dallas, TX, USA

    Patricio M. Polanco

Authors
  1. Ibrahim Nassour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricio M. Polanco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricio M. Polanco.

Ethics declarations

Conflict of Interest

Ibrahim Nassour and Patricio M. Polanco declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding

Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award No. UL1TR001105. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Additional information

This article is part of the Topical Collection on Surgery and Surgical Innovations in Colorectal Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nassour, I., Polanco, P.M. Current Management of Peritoneal Carcinomatosis From Colorectal Cancer: the Role of Cytoreductive Surgery and Hyperthermic Peritoneal Chemoperfusion. Curr Colorectal Cancer Rep 13, 144–153 (2017). https://doi.org/10.1007/s11888-017-0361-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-017-0361-x

Keywords

Search

Navigation